nifedipine

Adult Dosing .

Dosage forms:  CAP: 10 mg, 20 mg; ER TAB: 30 mg, 60 mg, 90 mg

angina, vasospastic

[immediate-release form]

Dose: 10-20 mg PO tid; Start: 10 mg PO tid, may incr. dose q7-14 days; Max: 180 mg/day; Info: pts w/ coronary artery spasm may require 20-30 mg PO tid-qid; taper dose gradually to D/C

[extended-release form]

Dose: 30-90 mg ER PO qd; Start: 30-60 mg ER PO qd, may incr. dose q7-14 days; Max: 90 mg/day ER; Info: do not cut/crush/chew ER tab; taper dose gradually to D/C

angina, chronic stable

[immediate-release form]

Dose: 10-20 mg PO tid; Start: 10 mg PO tid, may incr. dose q7-14 days; Max: 180 mg/day; Info: taper dose gradually to D/C

[extended-release form]

Dose: 30-90 mg ER PO qd; Start: 30-60 mg ER PO qd, may incr. dose q7-14 days; Max: 90 mg/day ER; Info: do not cut/crush/chew ER tab; taper dose gradually to D/C

HTN

[30-90 mg ER PO qd]

Start: 30-60 mg ER PO qd, may incr. dose q7-14 days; Max: 120 mg/day ER; Info: do not cut/crush/chew ER tab; taper dose gradually to D/C

hypertensive emergency, pregnancy-assoc. (off-label)

[10-20 mg PO q2-6h prn]

Start: 10-20 mg PO x1, may repeat dose x1 after 20min; Max: 180 mg/day

tocolysis (off-label)

[10-20 mg PO q4-8h x48h]

Start: 10 mg PO q20min; Max: 4 doses; Alt: load 30 mg PO x1, then 20 mg PO after 90min

high altitude pulmonary edema (off-label)

[30 mg ER PO q12h]

Start: 24h before ascent; Info: for prevention and tx; do not cut/crush/chew ER tab; D/C 5 days after peak arrival or upon descent

Raynaud phenomenon (off-label)

[immediate-release form]

Dose: 10-30 mg PO tid; Start: 10 mg PO tid, may incr. dose q7-14 days; Max: 180 mg/day; Info: taper dose gradually to D/C

[extended-release form]

Dose: 30-60 mg ER PO qd; Start: 30 mg ER PO qd, may incr. dose q7-14 days; Max: 120 mg/day ER; Info: do not cut/crush/chew ER tab; taper dose gradually to D/C

pulmonary arterial HTN (off-label)

[immediate-release form]

Dose: 20-60 mg PO tid; Start: 10 mg PO tid; Max: 240 mg/day; Info: for pts w/ positive vasoreactivity test; taper dose gradually to D/C

[extended-release form]

Dose: 120-240 mg/day ER PO divided qd-bid; Start: 30 mg ER PO qd; Max: 240 mg/day; Info: for pts w/ positive vasoreactivity test; do not cut/crush/chew ER tab; taper dose gradually to D/C

renal dosing

[no adjustment]

renal impairment: no adjustment

HD/PD: no adjustment; no supplement

hepatic dosing

[see below]

hepatic impairment: not defined, caution advised

Peds Dosing .

Dosage forms:  CAP: 10 mg, 20 mg; ER TAB: 30 mg, 60 mg, 90 mg

hypertrophic cardiomyopathy (off-label)

[0.6-0.9 mg/kg/day PO divided tid-qid]

Info: give w/ food; may bite and swallow cap; may puncture cap to measure smaller doses

Raynaud phenomenon (off-label)

[12 yo and older]

Dose: 0.2-1 mg/kg/day PO divided tid-qid; Start: 0.2 mg/kg/day PO divided tid, may incr. dose q7-14 days; Max: 180 mg/day; Info: give w/ food; may bite and swallow cap; may puncture cap to measure smaller doses; taper dose gradually to D/C

pulmonary arterial HTN (off-label)

[immediate-release form]

Dose: 1-2.5 mg/kg/dose PO bid; Start: 0.2-0.3 mg/kg/dose PO tid; Max: 240 mg/day; Info: for pts w/ positive vasoreactivity test; taper dose gradually to D/C

[extended-release form]

Dose: 2-3 mg/kg/day ER PO divided qd-bid; Start: after establishing effective dose w/ IR form; Max: 180 mg ER/day; Info: for pts w/ positive vasoreactivity test; do not cut/crush/chew ER tab; taper dose gradually to D/C

renal dosing

[no adjustment]

renal impairment: no adjustment

HD/PD: no adjustment; no supplement

hepatic dosing

[see below]

hepatic impairment: not defined, caution advised